Danaher: Biotech Strength And Cash Generation Reinforce A $250 Fair Value

Danaher Corporation is rated Buy with a target price of $250, implying 10.5% upside from $226.25. DHR's strong Q3 execution featured 4.5% revenue growth, margin expansion to 37.2%, and robust free cash flow conversion at 145%. Biotechnology drives growth while Life Sciences stagnates; management guides for modest FY25 growth and margin expansion in 2026.

Seeking Alpha • Dec 10, 2025

Danaher Announces Quarterly Dividend

WASHINGTON , Dec. 9, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.

PRNewsWire • Dec 9, 2025

6 Dividend Stocks Ready To Benefit From 2026's Rate-Shift Economy

Let's get our 2026 dividend shopping finished ahead of time, shall we?

Forbes • Dec 4, 2025

30% of the S&P 500 Is Mag 7 Tech Stocks, but This ETF Refuses to Own a Single One

The Magnificent 7 AI tech stocks have served as the rocket fuel propelling the S&P 500 on its bull run over the past few years.

24/7 Wall Street • Dec 2, 2025

HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders.

PRNewsWire • Nov 28, 2025

Danaher (DHR) Up 2% Since Last Earnings Report: Can It Continue?

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Nov 20, 2025

Danaher Corporation (DHR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Danaher Corporation ( DHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Rainer Blair - President, CEO & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division I think we'll kick it off. Welcome, everybody.

Seeking Alpha • Nov 18, 2025

3 More Good Stocks to Invest In After Earnings

These cheap stocks from wide-moat companies look attractive today.

Morningstar • Nov 18, 2025

The Big 3: TMO, DHR, VLO

As A.I. stocks take a beating on Wednesday's trading session, Dan Deming offers his thoughts and example options trades in healthcare and energy stocks. He explains his bullish theses behind Thermo Fisher Scientific (TMO), Danaher (DHR), and Valero Energy (VLO).

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon

A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.

The Motley Fool • Nov 12, 2025